This peptide blend combines CJC-1295 (no DAC), a growth hormone-releasing hormone analog, with Ipamorelin, a selective growth hormone secretagogue. It is typically dosed subcutaneously once daily, with a gradual increase from 100 mcg to 300 mcg of each peptide over an 8-16 week cycle to support natural growth hormone release.
- Combined action of GHRH analog and GH secretagogue.
- Targets pulsatile growth hormone release.
- Dosage gradually increases over the cycle.
- Administered once daily via subcutaneous injection.
- Requires reconstitution with bacteriostatic water.
Reconstitution
Vial strength
10 mg
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
1 unit = 0.01 mL = 33.3 mcg each peptide
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject the water slowly down the inside wall of the vial to prevent foaming.
- 3Gently swirl or roll the vial until the powder is completely dissolved; do not shake.
- 4Label the reconstituted vial with the date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1-2 | 100 mcg each | 3 units (0.03 mL) |
| Weeks 3-4 | 150 mcg each | 4.5 units (0.045 mL) |
| Weeks 5-6 | 200 mcg each | 6 units (0.06 mL) |
| Weeks 7-12 | 250–300 mcg each | 7.5–9 units (0.075–0.09 mL) |
Protocol detail
| Start | Begin with 100 mcg of each peptide daily. Increase the dose by approximately 50 mcg every 1–2 weeks, depending on individual tolerance. |
|---|---|
| Target | Aim to reach a daily dose of 200–300 mcg of each peptide by Weeks 5–12. |
| Frequency | Administer once per day via subcutaneous injection. |
| Cycle Length | Typically 8–12 weeks, with the possibility of extending to 16 weeks. |
| Timing | Inject either before bedtime or upon waking. Remember to rotate injection sites regularly. |
Overview at a glance
| Goal | Support pulsatile Growth Hormone (GH) release by synergistically stimulating GHRH and GHS pathways. |
|---|---|
| Schedule | Daily subcutaneous injections for an initial period of 8–12 weeks, with an option to extend to 16 weeks. |
| Dose Range | A gradual escalation from 100 mcg to 300 mcg of each peptide daily. |
| Reconstitution | Use 3.0 mL of bacteriostatic water per 10 mg vial, resulting in a total concentration of approximately 3.33 mg/mL to facilitate accurate unit measurements. |
| Storage | Lyophilized powder should be stored frozen; after reconstitution, keep refrigerated. Avoid repeated freezing and thawing. |
How it works
CJC-1295 (no DAC) functions as a modified growth hormone-releasing hormone (GHRH) analog, stimulating the pituitary gland to release endogenous growth hormone in a pulsatile manner. Studies have shown it can lead to sustained increases in growth hormone and IGF-1. Ipamorelin, a selective growth hormone secretagogue, triggers a rapid pulse of GH release without affecting other hormones like ACTH or cortisol. When these two peptides are combined, they are believed to act synergistically, supporting enhanced and more natural growth hormone secretion by targeting complementary pathways, which can contribute to overall revitalizing effects.
Reported effects
- Supports sustained elevation of Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1).
- Stimulates GH release without affecting ACTH, cortisol, or prolactin.
- May normalize growth in animal models with once-daily dosing.
- Generally well-tolerated.
Reported side effects
- Transient flushing
- Headache
- Injection-site reactions (redness, tenderness)
- Increased appetite
- Temporary water retention
- Mild tingling sensations
Storage
Lyophilised (unmixed)
Store at -20 °C (-4 °F) in a dry, dark place; minimize moisture exposure.
After reconstitution
Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~28 days; avoid freeze–thaw cycles. Protect from light.
Supplies
| Peptide vials | Based on 10 mg blend vials: approximately 3 vials for 8 weeks, 4 vials for 12 weeks, or 5 vials for 16 weeks. |
|---|---|
| Insulin Syringes | U-100 syringes, preferably 30- or 50-unit for smaller volumes. Estimate 7 syringes per week. |
| Bacteriostatic Water | 10 mL bottles: 1 bottle for 8-12 weeks, 2 bottles for 16 weeks (approx. 3.0 mL per vial). |
| Alcohol Swabs | Estimate 2 swabs per day (one for vial, one for injection site). |
Important notes
- Always use new, sterile insulin syringes and dispose of them safely in a sharps container.
- Rotate injection sites frequently (e.g., abdomen, thighs, upper arms) to minimize local irritation and prevent lipohypertrophy.
- Inject slowly and smoothly; wait a few seconds before withdrawing the needle.
- Track your daily dose and injection site rotation for consistency.
- For doses under 10 units as measured on a U-100 syringe, use 30- or 50-unit insulin syringes for improved precision.
Frequently asked questions
What is the key difference between CJC-1295 NO DAC and CJC-1295 DAC?
CJC-1295 NO DAC has a shorter half-life, leading to more natural, pulsatile growth hormone release, as it clears the system quicker. CJC-1295 DAC, with its longer half-life, provides a more sustained, but less pulsatile, elevation of growth hormone and IGF-1.
Can I mix this blend with other peptides?
While this particular protocol focuses on the CJC-1295 NO DAC + Ipamorelin blend, caution is always advised when combining peptides. Consult thorough research and possibly a healthcare professional for specific guidance on stacking peptides to avoid unwanted interactions.
Why is it recommended to inject before bed or upon waking?
Injecting before bed aligns with the body's natural sleep-induced growth hormone release cycles, potentially maximizing therapeutic effects. Injecting upon waking can also be effective by leveraging the natural cortisol cycle. Consistency in timing is generally more important than the exact time of day.
Is it normal to feel some side effects like tingling or water retention?
Yes, some individuals may experience mild side effects such as temporary water retention, increased appetite, or tingling sensations, especially when first starting the protocol or with dose increases. These are often transient and tend to subside as the body adjusts.
Educational reference only. These figures summarise how CJC-1295 NO DAC + Ipamorelin is commonly described in research literature and supplier documentation, including the CJC-1295 NO DAC + Ipamorelin listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
CJC-1295 DAC (2 mg Vial)
Long-acting GHRH analog for sustained growth hormone release.
CJC-1295 DAC + Ipamorelin Stack (CJC-1295 (2 mg) + Ipamorelin (5 mg))
Amplify growth hormone production with this synergistic peptide stack.
GHRP-2 (10 mg Vial)
Potent growth hormone secretagogue mimicking ghrelin's action.
GHRP-2 (5 mg Vial)
Synthetic peptide stimulating growth hormone release via ghrelin receptors.